期刊文献+

新型法尼基硫代水杨酰胺衍生物的设计、合成及抗肿瘤活性

Design,synthesis and antitumor activity of farnesylthiosalicylamide derivatives
下载PDF
导出
摘要 通过将法尼基硫代水杨酸(FTS)的羧基用各种胺进行胺化设计,合成得到11个法尼基硫代水杨酰胺衍生物(9a^9k),并对它们进行了体外抗肿瘤活性评价。实验表明其中的8个化合物对5种人肿瘤细胞具有较强的抗增殖活性,其中,化合物9k的细胞增殖抑制活性最强,对5种肿瘤细胞的IC50范围达6.05~8.16μmol/L,优于阳性对照FTS,与索拉非尼相当。此外,化合物9k可下调细胞内凋亡抑制蛋白Bcl-2的水平并上调促凋亡蛋白Bax和caspase-3,提示该化合物具有显著诱导肿瘤细胞凋亡的作用。 A series of farnesylthiosalicylamide derivatives (9a-9k) were designed and synthesized via condensating the carboxyl of farnesyhhiosalicylic acid(FTS) with different amines, and the in vitro biological activity was evaluated. It was observed that eight of them displayed strong antitumor activity against five human cancer cells in vitro. Notably, compound 9k exhibited the most active with the ICs0 values of 6.05-8.16 μmol/L range against the tested cancer cells, which were superior to those of FTS and even comparable to that of sorafenib in vitro. In addition, compound 9k down-regulated the protein of Bcl-2 and increased the expression levels of Bax and caspase-3 proteins, indicating that compound 9k could induce tumor cell apoptosis.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2015年第2期162-168,共7页 Journal of China Pharmaceutical University
基金 国家自然科学基金资助项目(No.81302628) 江苏省自然科学基金资助项目(No.BK2011389) 南通市应用研究资助项目(No.BK2012085)~~
关键词 法尼基硫代水杨酰胺 衍生物 合成 抗肿瘤活性 细胞凋亡 farnesylthiosalicylamide derivatives synthesis antitumor activity cell apoptosis
  • 相关文献

参考文献2

二级参考文献26

  • 1Goitre L, Trapani E, Trabalzini L, et al. The Ras superfamily of small GTPases : the unlocked secrets [ J ]. Methods Mol Biol, 2014,1 120:1 - 18.
  • 2Vigil D, Cherfils J, Rossman KL, et al. Ras superfamily GEFs and GAPs : validated and tractable targets for cancer therapy [ J ]. Nat Rev Cancer,2010,10 ( 12 ) : 842 - 857.
  • 3Takashima A, Failer DV. Targeting the RAS oncogene[ J]. Expert Opin Ther Targets ,2013,17 ( 5 ) :507 - 531.
  • 4Karachaliou N, Mayo C, Costa C, et al. KRAS mutations in lung cancer [ J ]. Clin Lung Cancer,2013,14 (3) :205 - 214.
  • 5Schubbert S, Shannon K, Bollag G. Hyperactive Ras in develop- mental disorders and cancer [ J ]. Nat Rev Cancer, 2007,7 ( 4 ) : 295 - 308.
  • 6Gysin S, Salt M, Young A, et al. Therapeutic strategies for targe- ting ras proteins [ J ]. Genes Cancer,2011,2 ( 3 ) : 359 - 372.
  • 7Wang YX, Kaiser CE, Frett B, et al. Targeting mutant KRAS for anticancer therapeutics : a review of novel small molecule modula- tars[ J]. J Med Chem,2013,56( 13 ) :5 219 -5 230.
  • 8Marciano D, Ben-Baruch G, Marom M, et al. Farnesyl derivatives of rigid carboxylic acids inhibitors of ras-dependent cell growth [J]. J Med Chem,1995,38(8) :1 267 - 1 272.
  • 9Barkan B, Cox AD, Kloog Y. Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize ceils to apoptosis[ J]. Onco- target,2013,4(2) :256 -268.
  • 10Charette N, De Saeger C, Horsmans Y, et al. Salirasib sensitizes hepatocarcinoma ceils to TRAIL-induced apoptosis through DR5and survivin-dependent mechanisms [ J ]. Cell Death Dis, 2013, 4:e471.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部